EQUITY RESEARCH MEMO

AB ANALITICA

Generated 5/11/2026

Executive Summary

Conviction (model self-assessment)55/100

AB ANALITICA is an Italian in vitro diagnostics (IVD) company founded in 2008 and headquartered in Padua. The company develops, produces, and markets a broad portfolio of diagnostic solutions for professional use, with expertise in molecular diagnostics (real-time PCR, next-generation sequencing) and immunoassays (ELISA/CLIA). Its offerings target infectious diseases, oncology, and genetic testing, serving hospitals, clinical laboratories, and research institutions. Despite being privately held, the company has established a presence in the European diagnostics market and is expanding its product range to address unmet clinical needs.

Upcoming Catalysts (preview)

  • Q4 2026CE-IVD certification for new NGS oncology panel60% success
  • Q2 2027Strategic distribution partnership for Middle East expansion40% success
  • Q3 2026Launch of multiplex real-time PCR respiratory panel70% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)